Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

testing; the therapeutic and commercial value of XL184 and our other compounds; our ability to initiate clinical trials for XL184 at the referenced times; and our ability to enter into new collaborations, continue existing collaborations and receive milestones and royalties under our collaborative agreements. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended March 28, 2008, and other filings with the Securities and Exchange Commission. We expressly disclaim any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 According to a new market ... - Global Industry Analysis, Size, Share, Growth, Trends and ... is estimated at USD 161,056.5 million in 2014 and ... from 2014 to 2020, to reach an estimated value ... drugs market is witnessing a significant growth due to ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... 2011 Operational and Financial Results ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Nov. 11, 2010 StemCyte, Inc., one of the ... companies, is proud to announce that the Company has ... U.S. Internal Revenue Service,s Qualifying Therapeutic Discovery Project (QTDP) ... fewer than 250 employees. The Patient Protection ...
... (Nasdaq: ARAY ), a global leader in the ... to present at the Lazard Capital Markets, Healthcare Conference in ... a.m. ET/7:30 a.m. PT. A live webcast of ... page of the Company,s Web site at http://www.accuray.com . ...
Cached Biology Technology:YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 2YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 3YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 4YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 5YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 6YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 7YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 8YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 9YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 10YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 11YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 12YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 13YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 14StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP) 2Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets' Healthcare Conference 2
(Date:7/24/2014)... Bhavani Iyer, O.D., a low vision specialist at The ... Medical School, has been awarded a grant to help ... with eyeglasses, medication or surgery. , Even with corrective ... at best. However, there are a variety of low ... to help offset their vision loss. , Iyer is ...
(Date:7/24/2014)... experts gathered at NJIT this week for an all-day ... U.S. Environmental Protection Agency (EPA) to dredge toxic sediment ... , The EPA has called the plan, which proposes ... capping sections of the riverbed, one of the largest ... be dredged and disposed off-site. , "We need to ...
(Date:7/24/2014)... To reduce fire hazard in the United States, wildland ... woody shrubs and suppressed trees (ladder fuels). These ... periods of low fire danger in order to dispose ... hazardous air pollutants, managers often cover all or part ... referred to as agricultural plastic, in order to keep ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... to the growing list of genetic variants that determine ... by Cell Press on December 30 in the ... previously unknown variants associated with height and might provide ... Although environmental variables can impact attained adult height, ...
... large quantities of nitrate-rich fertilizer to realize optimal ... to balance the amount of nitrogen needed for ... leach into ground and surface waters. Increased interest ... to identify genotypes that have a characteristic called ...
... producers have traditionally relied heavily on hand thinning, a ... increasing labor costs and a limited workforce, peach and ... such as string thinners to minimize the need for ... promising results when it was evaluated in four U.S. ...
Cached Biology News:Large-scale analysis identifies new genetic alterations associated with height 2Improving nitrogen use efficiency lessens environmental impact 2Hybrid string blossom thinner tested in peach orchards 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... of X-ray crystallography services for structure-based ... to its pharmaceutical and biotechnology clients. ... drug-like fragments to the active sites ... scientists to develop novel, high-affinity inhibitors. ...
...
... monitoring acetylcholinesterase (AChE) activity. This is a ... min), non-radioactive and easy to use assay ... substrate, acetylcholine. A series of coupled enzyme ... into a change in luminescence. Inhibitors of ...
Biology Products: